The current clinical management of Huntington's disease

被引：101

作者：

Phillips, Wendy ^{[1
,2
]}

Shannon, Kathleen M. ^{[3
]}

Barker, Roger A. ^{[1
,2
]}

机构：

[1] Cambridge Ctr Brain Repair, Cambridge CB2 2PY, England

[2] Addenbrookes Hosp, Dept Neurol, Cambridge, England

[3] Rush Univ, Med Ctr, Chicago, IL 60612 USA

来源：

MOVEMENT DISORDERS | 2008年 / 23卷 / 11期

基金：

英国医学研究理事会;

关键词：

Huntington's disease; juvenile Huntington's disease; management; clinical features; UHDRS; biomarkers; multidisciplinary;

D O I：

10.1002/mds.21971

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Huntingtons disease is a neurodegenerative condition. characterized by movement disorders, cognitive decline. and psychiatric disturbance. We review the pharmacological management of the various movement disorders associated with the disease. the cognitive decline and the commonly encountered behavioral disturbances. We discuss the nonclassical features of the disease. important in the management of these patients. Nonpharmacological Support including genetic counseling and therapy and the importance of palliative care are also addressed. Finally, experimental approaches that may soon impact upon clinical practice are discussed. (c) 2008 Movement Disorder Society.

引用

页码：1491 / 1504

页数：14

共 154 条

[1]

The use of quantitative oculometry in the assessment of Huntington's disease [J].

Ali, FR ;

Michell, AW ;

Barker, RA ;

Carpenter, RHS .

EXPERIMENTAL BRAIN RESEARCH, 2006, 169 (02) :237-245

[2]

THE RELATIONSHIP BETWEEN TRINUCLEOTIDE (CAG) REPEAT LENGTH AND CLINICAL-FEATURES OF HUNTINGTONS-DISEASE [J].

ANDREW, SE ;

GOLDBERG, YP ;

KREMER, B ;

TELENIUS, H ;

THEILMANN, J ;

ADAM, S ;

STARR, E ;

SQUITIERI, F ;

LIN, BY ;

KALCHMAN, MA ;

GRAHAM, RK ;

HAYDEN, MR .

NATURE GENETICS, 1993, 4 (04) :398-403

[3]

Assessment of simple movements and progression of Huntington's disease [J].

Andrich, Juergen ;

Saft, Carsten ;

Ostholt, Natalie ;

Mueller, Thomas .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (04) :405-407

[4]

[Anonymous], 2002, Huntington's disease

[5]

Task-set switching deficits in early-stage Huntington's disease: Implications for basal ganglia function [J].

Aron, AR ;

Watkins, L ;

Sahakian, BJ ;

Monsell, S ;

Barker, RA ;

Robbins, TW .

JOURNAL OF COGNITIVE NEUROSCIENCE, 2003, 15 (05) :629-642

[6]

BARKER RA, 2007, ACNR, V3, P19

[7]

A progressive and cell non-autonomous increase in striatal neural stem cells in the Huntington's disease R6/2 mouse [J].

Batista, Claudia M. C. ;

Kippin, Tod E. ;

Willaime-Morawek, Sandrine ;

Shimabukuro, Marilia Kimie ;

Akamatsu, Wado ;

van der Kooy, Derek .

JOURNAL OF NEUROSCIENCE, 2006, 26 (41) :10452-10460

[8]

Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders [J].

Bhandary, AN ;

Masand, PS .

PSYCHOSOMATICS, 1997, 38 (04) :389-391

[9]

Effectiveness of physiotherapy, occupational therapy, and speech pathology for people with Huntington's disease: A systematic review [J].

Bilney, B ;

Morris, ME ;

Perry, A .

NEUROREHABILITATION AND NEURAL REPAIR, 2003, 17 (01) :12-24

[10]

A systematic review of the treatment studies in Huntington's disease since 1990 [J].

Bonelli, Raphael M. ;

Hofmann, Peter .

EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (02) :141-153

← 1 2 3 4 5 6 7 8 9 10 →